A Phase 1 interventional study of D-2570 and Placebo in Healthy Volunteer, sponsored by InventisBio Co., Ltd. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.
Double blind study evaluating the safety, tolerability and PK data of D-2570/placebo in healthy volunteers.
InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: D-2570 · Drug: Placebo
Drug: D-2570 · Drug: Placebo
Drug: D-2570 · Drug: Placebo
D-2570
Placebo
Incidence of adverse events
Incidence of adverse events
Time frame: From Informed Consent through study completion, an average of 48 days
Result of Pharmacokinetic endpoint
Tmax
Time frame: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
Cmax
Time frame: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
t1/2
Time frame: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
MRT
Time frame: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
AUC0-∞
Time frame: From Randomization through study completion, an average of 20 days.
Result of Pharmacokinetic endpoint
AUC0-t
Time frame: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
CL/F
Time frame: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
Vz/F
Time frame: From Randomization through study completion, an average of 20 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Jun 2026, 6 months.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D-2570